Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 8,250 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans

NCT01660009
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Glycemic clamping
Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 31, 2026, 1:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Normal Human Plasma Level of iNOS Study

NCT01605695
View directory record Official record
Conditions
Normal Human Plasma Level of iNOS
Interventions
Not listed
Lead sponsor
Research & Diagnostic Antibodies
Industry
Eligibility
18 Years to 79 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
North Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Not applicable Interventional Results available

Immunogenicity to Human Papillomavirus Vaccine (Gardasil) Among IBD Patients on Immunosuppressive Therapy

NCT00727636
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Gardasil vaccine
Biological
Lead sponsor
Boston Children's Hospital
Other
Eligibility
9 Years to 26 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2011 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

NCT02833844
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
20
States / cities
Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 31, 2026, 1:06 AM EDT
Not listed No phase listed Observational

Stem Cells Found in the Abdominal Cavity in Humans

NCT00576264
View directory record Official record
Conditions
Intra-abdominal Surgery
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 31, 2026, 1:06 AM EDT
Terminated Not applicable Interventional

Conversational Agents to Improve HPV Vaccine Acceptance in Primary Care (ECA-HPV)- Clinical Trial

NCT06367699
View directory record Official record
Conditions
Human Papilloma Virus
Interventions
Usual Care, ECA-HPV App with Clinic Notification and Adolescent Functions Disabled, ECA-HPV App with Clinic Notification Function Enabled, ECA-HPV App with Adolescent Function Enabled, ECA-HPV App with Clinic Notification and Adolescent Functions Enabled
Behavioral
Lead sponsor
Tufts Medical Center
Other
Eligibility
8 Years to 12 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Oct 31, 2026, 1:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of Proliferative Potential of H-PBSC Based on Demographics and Cryopreservation Time

NCT05573412
View directory record Official record
Conditions
Healthy
Interventions
Cellular analysis
Other
Lead sponsor
Andrews Research & Education Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Gulf Breeze, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Assess the Immune Response and Safety of a Vaccine Against Influenza in Adults 18 Years of Age and Older

NCT07121192
View directory record Official record
Conditions
Influenza, Human
Interventions
Flu mRNA (Formulation A), Flu mRNA (Formulation B), Comparator 1, Comparator 2, Comparator 3
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
776 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
22
States / cities
Anniston, Alabama • Fair Oaks, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

NCT02831764
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir (DTG), Lamivudine (3TC), Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Phase 3 Interventional Results available

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

NCT02269163
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%
Biological
Lead sponsor
Prometic Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
13
States / cities
Irvine, California • Los Angeles, California • Centennial, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer

NCT01643993
View directory record Official record
Conditions
Control Media Only, Study hCG and Media
Interventions
hCG at the Time of Embryo Transfer, Control
Other
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 43 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
2
States / cities
Basking Ridge, New Jersey • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 31, 2026, 1:06 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effects of Triphala and VSL#3 Probiotic Supplementation on Stool Microbiome Profiles and Inflammation

NCT03907501
View directory record Official record
Conditions
Human Microbiome
Interventions
Synbiotic, Probiotic, Placebo
Dietary Supplement
Lead sponsor
University of California, San Diego
Other
Eligibility
65 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Oct 31, 2026, 1:06 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)

NCT04179032
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 31, 2026, 1:06 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

NCT02194998
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Phase 2 Interventional Results available

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

NCT01441596
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Vinorelbine, Investigator's choice of treatment, afatinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2015 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes

NCT02965924
View directory record Official record
Conditions
Assess Phenylephrine on EVP and IOP
Interventions
Phenylephrine 2.5%
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Phase 3 Interventional Results available

Anakinra to Prevent Post-infarction Remodeling

NCT00789724
View directory record Official record
Conditions
ST Segment Elevation Acute Myocardial Infarction
Interventions
Anakinra, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2017 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans

NCT06333496
View directory record Official record
Conditions
Blood Sugar; High, Overweight and Obesity, Fat Burn, Obesity, Heart Health Markers
Interventions
GLP-1 Booster (GB)
Dietary Supplement
Lead sponsor
Alpine Biotech LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects

NCT03309241
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06882961, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears

NCT00084903
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Colposcopic biopsy, Light-Scattering Spectroscopy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,070 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of AMP Human Sodium Bicarbonate Lotion on Dehydrated Heat Stress

NCT05092854
View directory record Official record
Conditions
Fluid Retention, Sodium Retention, Heat Stress, Dehydration (Physiology), Renal Injury, Electrolyte and Fluid Balance Conditions
Interventions
PR Lotion - AMP Human Performance, Placebo Lotion, AminoVital - Rapid Recovery, Placebo Supplement
Other
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 45 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 24, 2022 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Phase 1 Interventional Results available

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors

NCT04853017
View directory record Official record
Conditions
Minimal Residual Disease, KRAS G12D, KRAS G12R, NRAS G12D, NRAS G12R, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Cholangiocarcinoma, Bile Duct Cancer, Gallbladder Carcinoma
Interventions
ELI-002 2P
Drug
Lead sponsor
Elicio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 31, 2026, 1:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reactivating Specific Memories During Sleep in Conjunction with a Suppression Context

NCT04702750
View directory record Official record
Conditions
Sleep, Consolidation
Interventions
Targeted memory reactivation (odors), Targeted memory reactivation (sounds)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 35 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 31, 2026, 1:06 AM EDT
Not listed Phase 1 Interventional

Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609A

NCT03950297
View directory record Official record
Conditions
Solid Tumors
Interventions
609A
Drug
Lead sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2020 · Synced Oct 31, 2026, 1:06 AM EDT